Instrument Inactif

Autres langues Clementia Pharmaceuticals Inc

Actions

CA1855751071

Recherche biotechnologique et médicale

Autres langues

11/04/19	Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
09/04/19	Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.
25/02/19	Trade tariff reprieve triggers relief in European shares
25/02/19	GLOBAL MARKETS LIVE: Roche, AT&T, Spotify, General Electric…
25/02/19	Clementia Pharmaceuticals : Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion
20/02/19	Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference
30/11/18	Clementia Announces the Departure of Chief Commercial Officer
21/11/18	Clementia to Present at the Evercore ISI HealthCONx Conference
07/11/18	Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
30/10/18	Clementia Announces Pricing of Public Offering of Common Shares
29/10/18	Clementia Announces Proposed Public Offering of Common Shares
23/10/18	Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
02/10/18	Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
26/09/18	Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
05/09/18	Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
16/08/18	Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
09/08/18	Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
31/05/18	Clementia to Present at the Jefferies 2018 Global Healthcare Conference
23/05/18	Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
09/05/18	Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates
20/04/18	Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
06/03/18	Clementia to Present at the Cowen and Company 38th Annual Health Care Conference
28/02/18	Clementia Reports 2017 Operating Results and Business Highlights
07/02/18	Clementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference
31/01/18	Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors